化痰祛瘀法联合艾拉莫德治疗白塞综合征的临床效果
|
摘要
目的探讨化痰祛瘀法联合艾拉莫德对白塞综合征患者炎症指标变化、临床疗效以及安全性的观察。方法将2015年12月～2017年2月在邯郸市中医院治疗的50例白塞综合征患者,按照随机数字表法分为中西药组25例和西药组25例,中西药组用化痰祛瘀方加减联合艾拉莫德片,西药组用艾拉莫德片,比较两组患者治疗2个月后的临床疗效、C反应蛋白水平、免疫球蛋白A水平和药物不良反应。结果治疗后两组血清C反应蛋白、免疫球蛋白A水平均较治疗前下降(P <0.01),中西药组患者C反应蛋白、免疫球蛋白A水平均明显低于西药组,差异有统计学意义(P <0.05);中西药组临床疗效高于西药组,差异有统计学意义(P <0.05);不良反应发生率中西药组低于西药组(P <0.05)。结论化痰祛瘀法联合艾拉莫德能降低白塞综合征患者的C反应蛋白、免疫球蛋白A水平,提高临床疗效。
Objective To explore the effect of therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod in treating Beh觭et syndrome patients on the changes of inflammatory indices, clinical efficacy and safety.Methods From December 2015 to February 2017, 50 patients with Beh觭et syndrome in Handan Hospital of Traditional Chinese Medicine were selected. They were divided into Chinese and Western medicine group 25 cases and Western medicine group 25 cases. Chinese and Western medicine group was given reduce phlegm and eliminate stasis decoction and Iguratimod Tablets, Western medicine group was given Iguratimod Tablets. Clinical efficacy, C reactive protein level, immunoglobulin A level, adverse reactions of medicine in the two groups were compared after 2 months′ treatment.Results After treatment, C reactive protein and immunoglobin A levels decreased than those before treatment(P < 0.01),the levels of C reactive protein and immunoglobulin A in the Chinese and Western medicine group were significantly lower than those in the western medicine group(P < 0.05). The clinical efficacy of the Chinese and Western medicine group was higher than the Western medicine group(P < 0.05); and adverse reactions rate in the Chinese and Western medicine group was lower than Western medicine group(P < 0.05). Conclusion Therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod can reduce Beh觭et syndrome patients′ C reactive protein and immunoglobulin A levels, improve clinical efficacy.
Objective To explore the effect of therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod in treating Beh觭et syndrome patients on the changes of inflammatory indices, clinical efficacy and safety.Methods From December 2015 to February 2017, 50 patients with Beh觭et syndrome in Handan Hospital of Traditional Chinese Medicine were selected. They were divided into Chinese and Western medicine group 25 cases and Western medicine group 25 cases. Chinese and Western medicine group was given reduce phlegm and eliminate stasis decoction and Iguratimod Tablets, Western medicine group was given Iguratimod Tablets. Clinical efficacy, C reactive protein level, immunoglobulin A level, adverse reactions of medicine in the two groups were compared after 2 months′ treatment.Results After treatment, C reactive protein and immunoglobin A levels decreased than those before treatment(P < 0.01),the levels of C reactive protein and immunoglobulin A in the Chinese and Western medicine group were significantly lower than those in the western medicine group(P < 0.05). The clinical efficacy of the Chinese and Western medicine group was higher than the Western medicine group(P < 0.05); and adverse reactions rate in the Chinese and Western medicine group was lower than Western medicine group(P < 0.05). Conclusion Therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod can reduce Beh觭et syndrome patients′ C reactive protein and immunoglobulin A levels, improve clinical efficacy.
引文
[1] Hatemi G,Seyahi E,Fresko I,et al. Beh觭et′s syndrome:a critical digest of the 2013-2014 literature[J]. Clin Exp Rheumato1,2014,32(4 Suppl 84):S112-S122.
[2] Vaiopoulos AG,Sfikakis PP,Kanakis MA,et al. Gastrointestinal manifestations of Beh觭et′s disease:advances in evaluation and management[J]. Clin Exp Rheumatol,2014,32(4 Suppl 84):S140-S148.
[3]中华医学会风湿病学分会.白塞综合征诊治指南[J].中华风湿病学杂志,2003,7(12):762-764.
[4] Davatchi F,Sadeghi Abdollahi B,Chams-Davatchi C,et al. The saga of diagnostic/classification criteria in Beh觭et′s disease[J]. Int J Rheum Dis,2015,18(6):594-605.
[5]周仲瑛.中医内科学[M].北京:中国中医药出版社,2011:467-468.
[6]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:273.
[7] Emmi G,Silvestri E,Squatrito D,et al. Beh觭et′s syndrome pathophysiology and potential therapeutic targets[J]. Intern Emerg Med,2014,9(3):257-265.
[8]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:830-842.
[9]郭衍秋,潘丽丽,万瑾,等.白塞病大血管病变的临床特点分析[J].中国医药,2017,12(5):766-770.
[10]李国铨,刘楠,郑顔萍.白塞综合征20例临床分析[J].海南医学,2016,27(21):3552-3553.
[11]宋星慧,任立敏.白塞综合征血管病变特点的临床分析[J].中华临床医师杂志:电子版,2013,7(7):3150-3152.
[12]秦准,赵昶,程颐,等.白塞病血管病变彩色多普勒超声特点分析[J].中国医药,2016,11(12):1855-1858.
[13] Hisamatsu T,Naganuma M,Matsuoka K,et al. Diagnosis and management of intestinal Beh觭et′s disease[J]. Clin J Gastro enterol,2014,25(7):205-212.
[14] Vaccarino L,Triolo G,Accardo-Palombo A,et al. Pathological implications of Thl Th2 cytokine geneticvariants in Beh觭et′s disease:Data from a pilot study in a Sicilian population[J]. Biochem Genet,2013,51(11/12):967-975.
[15]王梦涛,倪丹红,王晓元,等.艾拉莫德对类风湿关节炎患者CD3+T细胞IFN-γ及细胞因子IL-6调节作用的研究[J].中国地方病防治杂志,2016,31(12):1345-1346.
[16]孟德钎,潘文友,李鞠,等.甲氨蝶呤联合艾拉莫德治疗难冶性类风湿关节炎的效果[J].中国医药导报,2016,13(3):137-141.
[17]康成辰,刘昆仑,张立亭,等.张鸣鹤教授治疗白塞综合征中甘草的应用[J].四川中医,2014,32(4):18-19.
[18]夏惠文.高冬来副主任中医师治疗白塞综合征经验[J].中医研究,2014,27(4):38-39.
[19]侯学敏,王守儒.王守儒教授中西医结合治疗白塞综合征经验总结[J].中医临床研究,2015,1(2):68-69.
[20]成洁,董军胜.徐玲主任医师从脾胃论治白塞综合征的经验[J].陕西中医,2014,35(4):477-478.
[21]孙剑虹,徐串联,严宇仙.解毒化瘀通络方治疗白塞氏病的临床研究[J].中国中医药科技,2014,21(5):488-490.
[22]周倩,吴皓.半夏总生物碱抗炎作用研究[J].中药药理与临床,2006,22(34):87-88.
[23]梁学清,李丹丹,黄忠威.茯苓药理作用研究进展[J].河南科技大学学报:医学版,2012,30(2):154-156.
[24]杨志军,李初谊,郭胜,等.当归及不同配伍对环磷酰胺诱导的小鼠免疫器官、吞噬功能的影响[J].西部中医药,2013,26(4):8-10.
[25]胡荣,杨金荣,王斌,等.不同配伍桃仁对赤芍水煎液中芍药苷含量的影响[J].中药与临床,2013,4(1):16-18.
[2] Vaiopoulos AG,Sfikakis PP,Kanakis MA,et al. Gastrointestinal manifestations of Beh觭et′s disease:advances in evaluation and management[J]. Clin Exp Rheumatol,2014,32(4 Suppl 84):S140-S148.
[3]中华医学会风湿病学分会.白塞综合征诊治指南[J].中华风湿病学杂志,2003,7(12):762-764.
[4] Davatchi F,Sadeghi Abdollahi B,Chams-Davatchi C,et al. The saga of diagnostic/classification criteria in Beh觭et′s disease[J]. Int J Rheum Dis,2015,18(6):594-605.
[5]周仲瑛.中医内科学[M].北京:中国中医药出版社,2011:467-468.
[6]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:273.
[7] Emmi G,Silvestri E,Squatrito D,et al. Beh觭et′s syndrome pathophysiology and potential therapeutic targets[J]. Intern Emerg Med,2014,9(3):257-265.
[8]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:830-842.
[9]郭衍秋,潘丽丽,万瑾,等.白塞病大血管病变的临床特点分析[J].中国医药,2017,12(5):766-770.
[10]李国铨,刘楠,郑顔萍.白塞综合征20例临床分析[J].海南医学,2016,27(21):3552-3553.
[11]宋星慧,任立敏.白塞综合征血管病变特点的临床分析[J].中华临床医师杂志:电子版,2013,7(7):3150-3152.
[12]秦准,赵昶,程颐,等.白塞病血管病变彩色多普勒超声特点分析[J].中国医药,2016,11(12):1855-1858.
[13] Hisamatsu T,Naganuma M,Matsuoka K,et al. Diagnosis and management of intestinal Beh觭et′s disease[J]. Clin J Gastro enterol,2014,25(7):205-212.
[14] Vaccarino L,Triolo G,Accardo-Palombo A,et al. Pathological implications of Thl Th2 cytokine geneticvariants in Beh觭et′s disease:Data from a pilot study in a Sicilian population[J]. Biochem Genet,2013,51(11/12):967-975.
[15]王梦涛,倪丹红,王晓元,等.艾拉莫德对类风湿关节炎患者CD3+T细胞IFN-γ及细胞因子IL-6调节作用的研究[J].中国地方病防治杂志,2016,31(12):1345-1346.
[16]孟德钎,潘文友,李鞠,等.甲氨蝶呤联合艾拉莫德治疗难冶性类风湿关节炎的效果[J].中国医药导报,2016,13(3):137-141.
[17]康成辰,刘昆仑,张立亭,等.张鸣鹤教授治疗白塞综合征中甘草的应用[J].四川中医,2014,32(4):18-19.
[18]夏惠文.高冬来副主任中医师治疗白塞综合征经验[J].中医研究,2014,27(4):38-39.
[19]侯学敏,王守儒.王守儒教授中西医结合治疗白塞综合征经验总结[J].中医临床研究,2015,1(2):68-69.
[20]成洁,董军胜.徐玲主任医师从脾胃论治白塞综合征的经验[J].陕西中医,2014,35(4):477-478.
[21]孙剑虹,徐串联,严宇仙.解毒化瘀通络方治疗白塞氏病的临床研究[J].中国中医药科技,2014,21(5):488-490.
[22]周倩,吴皓.半夏总生物碱抗炎作用研究[J].中药药理与临床,2006,22(34):87-88.
[23]梁学清,李丹丹,黄忠威.茯苓药理作用研究进展[J].河南科技大学学报:医学版,2012,30(2):154-156.
[24]杨志军,李初谊,郭胜,等.当归及不同配伍对环磷酰胺诱导的小鼠免疫器官、吞噬功能的影响[J].西部中医药,2013,26(4):8-10.
[25]胡荣,杨金荣,王斌,等.不同配伍桃仁对赤芍水煎液中芍药苷含量的影响[J].中药与临床,2013,4(1):16-18.